OnBioVC NEWS:

- OnBioVC Announces Beta Launch of Service
- OnBioVC-INDEX(TM) Updated thru SEP 2009
- OnBioVC SEP Trend Analysis, now available
- OnBioVC 2009 Year-in-Review, coming soon

SEARCH THE OnBioVC DATABASE:

26

Apr

2009

Ambrx, Inc.: Series D $10M

Posted in I - Series D, Q - 2Q09, R - WEST, X - Antibody, X - Growth Deficiency, X - Multiple Sclerosis, XX - CA

Ambrx (La Jolla, CA) a clinical-stage protein therapeutic company focused growth deficiency, closed a $10M Series D financing. Participants include Merck Serono, 5AM Ventures, Aravis Ventures, CMEA Capital, Maverick Capital, Versant Ventures and Tavistock Life Sciences.

Venture Capital Investors
5AM Ventures Abingworth Management Advanced Technology Ventures Amgen Ventures ARCH Venture Partners Aurora Funds Bay City Capital Bessemer Venture Partners Burrill & Co. Chicago Growth Partners CHL Medical Partners Clarus Ventures Comvest Delphi Ventures DeNovo Ventures DFJ Mercury Domain Associates Edmond de Rothschild Investment Partners Essex Woodlands Health Ventures Foundation Medical Partners HBM Bioventures Imperial Innovations Interwest Partners Kleiner Perkins Life Science Partners Life Sciences Partners Mohr Davidow Ventures MPM Capital MVM Life Science Partners New Enterprise Associates Novartis Ventures Funds Novo Ventures Oakwood Medical Investors Oxford Finance Polaris Venture Partners Quaker BioVentures Scale Venture Partners SV Life Sciences Texas Emerging Technology Fund Thomas McNerney Partners Venrock Ventech Wellcome Trust Ysios Capital Partners

OnBioVC Friends

IguanaBio
EyeOnFDA
Patent Baristas
Pharma's Cutting Edge
MedTechIQ
The Antibody Blog
BioJobBlog

OnBioVC Partners